TABLE 1.
Characteristics of individuals evaluated by the individual proviral sequencing assaya
| Donor ID | Age (yrs) | Sex | Raceb | Nadir CD4 T-cell count (cells/mm3) | No. of yrs on ARTc | Current CD4+ T-cell count (cells/mm3) | No. of HIV-1 DNA copies/106 PBMC | Current ART regimend |
|---|---|---|---|---|---|---|---|---|
| R-09 | 73 | Male | C | 105 | 10 | 380 | 1,533 | TDF/FTC/EFV |
| C-03 | 43 | Male | C | 10 | 9 | 416 | 2,505 | DRV/r/ETV/DTG |
| C-02 | 62 | Male | AA | 286 | 18 | 1,022 | 373 | TDF/FTC/EFV |
| F-07 | 59 | Male | AA | 314 | 19 | 1,023 | 1,603 | ABC/3TC/EFV |
| K-01 | 55 | Female | AA | 133 | 2 | 533 | 1,383 | TDF/FTC/DRV/r |
| Median | 59 | 133 | 10 | 533 | 1,533 | |||
a
Data modified from reference 15.
b
C, Caucasian; AA, African American.
c
Years on antiretroviral therapy (ART) at the time of initial evaluation.
d
Antiretroviral drugs were ABC (abacavir), ATV/r (atazanavir/ritonavir), DRV/c (darunavir/cobicistat), DRV/r (darunavir/ritonavir), DTG (dolutegravir), EFV (efavirenz), ETV (etravirine), FTC (emtricitabine), TDF (tenofovir disoproxil fumarate), and 3TC (lamivudine).